Doctolib is a technology company.
Doctolib has raised $218.0M across 3 funding rounds.
Doctolib has raised $218.0M in total across 3 funding rounds.
Doctolib is a leading European healthcare technology company that provides an all-in-one digital platform for appointment booking, telemedicine, electronic health records (EHR), and practice management tools, primarily serving independent healthcare professionals, hospitals, and patients in France, Germany, Italy, and the Netherlands.[1][2][4] It solves key pain points in healthcare by streamlining patient scheduling, reducing administrative burdens (saving doctors ~1.5 hours weekly and cutting no-shows by 60%), enabling remote consultations, and integrating AI-driven features like automated summaries and prescription tools, with over 450,000 professionals and 80-90 million patients using the platform.[2][5][7] Growth has been explosive, fueled by COVID-19 expansion, a €500 million funding round in 2022 at €5.8 billion valuation, and product launches like Doctolib Médecin (EHR SaaS at €135/month) and Doctolib Teams (messaging app).[1][2]
Founded in 2013 in Paris, France, by Stanislas Niox-Chateau and co-founders who identified the inefficiency of outdated phone-based appointment scheduling in healthcare, Doctolib launched as a simple booking platform to connect patients with nearby practitioners 24/7.[2][3][4][9] The idea emerged from recognizing a "clear gap" in digitizing healthcare access, quickly gaining traction with 45,000 doctors and 1,400 facilities early on.[3] Pivotal moments include COVID-19 acceleration, expanding into telemedicine, EHR, and messaging; international launches in Germany and Italy; and a 2022 funding round supporting organic and acquisitive growth, scaling from 1,000 to 3,000 employees.[1][7]
Doctolib stands out through its SaaS-enabled marketplace model, creating powerful network effects with 340,000+ professionals and 70-90 million monthly patient visitors, dominating France and expanding in Germany/Italy.[1][2]
Doctolib rides the digital health transformation wave, accelerated by COVID-19, addressing fragmented European healthcare with interoperable tools linking national EHRs (e.g., France's DMP, Germany's EPA).[1][5] Timing aligns with rising telemedicine demand, clinician burnout from admin tasks, and EU cross-border care needs, positioning it as Europe's #1 platform amid regulatory pushes for digitization.[3][5][7] It influences the ecosystem by empowering 450,000+ providers to focus on care, fostering patient responsibility (e.g., via waitlists), and enabling scalability across 30+ cities, while integrating AI to redefine workflows without replacing human elements.[5][6][9]
Doctolib's trajectory points to a full-service healthcare ecosystem, evolving beyond bookings into end-to-end patient journeys with deeper clinical/financial integrations, cross-border connectivity, and AI enhancements for personalized care.[1][5] Key trends like EU health data interoperability, AI adoption in medicine, and geographical push (beyond current markets) will propel growth, potentially solidifying its €5.8B valuation leader status.[1][5] Influence may grow by setting standards for user-first e-health, bridging professionals and patients in a post-pandemic world—reinventing the system they set out to fix in 2013.[4]
Doctolib has raised $218.0M in total across 3 funding rounds.
Doctolib's investors include Accel, Balderton Capital, Kitchen Table Partners, Sapphire Ventures, Partech Ventures, Thibaud Elziere.
Doctolib has raised $218.0M across 3 funding rounds. Most recently, it raised $170.0M Series E in March 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2019 | $170.0M Series E | Accel, Balderton Capital, Kitchen Table Partners, Sapphire Ventures | |
| Jan 1, 2017 | $28.0M Series C | Accel, Balderton Capital, Kitchen Table Partners, Partech Ventures, Sapphire Ventures, Thibaud Elziere | |
| Oct 1, 2015 | $20.0M Series B | Accel, Balderton Capital, Kitchen Table Partners, Partech Ventures, Sapphire Ventures, Thibaud Elziere |